A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans
A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans
M. Michel,E. Mayoux,V. Vallon
2015 · DOI: 10.1007/s00210-015-1134-1
Naunyn-Schmiedeberg's Archives of Pharmacology · 63 Citations
TLDR
The SGLT2 inhibitor empagliflozin improves glucose metabolism by enhancing urinary glucose excretion; upon chronic administration, the reductions in blood glucose levels are associated with beneficial effects on cardiovascular and renal complications of diabetes.